Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Day: June 25, 2024
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived...
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and...
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval...
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who...
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track to complete Anaphylm...
LifeMD Launches Commercial Health Insurance Acceptance for its Primary Care Services, Including Weight Management
Phased Geographic Rollout to be Followed by Acceptance of MedicareNEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq:...
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
SHANGHAI, June 25, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Zevra Therapeutics Expands Executive Leadership Team
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION,...
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation...
Kraig Biocraft Laboratories Increases Spider Silk Production with Next Generation of Hybrid Eggs Completed
ANN ARBOR, Mich., June 25, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"),...
ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor
- Market Authorisation Application (MAA) for UM171 Cell Therapy accepted under an accelerated assessment procedure by the European Medicines Agency...
ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI...
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Breckenridge Distillery Releases Award-Winning Collectors Art Series Collaboration With Abby Wren
For its Fourth Annual Collectors Art Series, Breckenridge Distillery Partners with California Artist to Create Label for Its New, Limited...
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved...
ROSE LifeScience announces quality upgrade to top-selling Pure Laine Big Pleasures
HUNTINGDON, Quebec, June 25, 2024 (GLOBE NEWSWIRE) -- ROSE LifeScience Inc. (“ROSE”), a major Québec cannabis producer, distributor, and marketer,...
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical...
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose)...